A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants

Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study

(2018) Shamez N Ladhani et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age

(2018) Susan J. Ermlich et al.   VACCINE

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants

(2018) David Greenberg et al.   VACCINE

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-Analysis of Observational Studies

(2018) Heather L Sings et al.   CLINICAL INFECTIOUS DISEASES

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

(2017) Ángela Domínguez et al.   PLoS One

Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media

(2016) Shalom Ben-Shimol et al.   CLINICAL INFECTIOUS DISEASES

Impact of 10- and 13-valent pneumococcal conjugate vaccines on incidence of invasive pneumococcal disease in children aged under 16 years in Germany, 2009 to 2012

(2015) S Weiss et al.   Eurosurveillance

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

(2015) Pauline A Waight et al.   LANCET INFECTIOUS DISEASES

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Safety, Tolerability and Immunogenicity of 15-valent Pneumococcal Conjugate Vaccine in Toddlers Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine

(2015) Ajoke Sobanjo-ter Meulen et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012

(2015) A. Lepoutre et al.   VACCINE

Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults

(2015) Richard McFetridge et al.   VACCINE

Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine

(2015) Alain Luxembourg et al.   Human Vaccines & Immunotherapeutics

Pneumococcal infection in adults: burden of disease

(2013) J.J.C. Drijkoningen et al.   CLINICAL MICROBIOLOGY AND INFECTION

The history of pneumococcal conjugate vaccine development: dose selection

(2013) Jan T Poolman et al.   Expert Review of Vaccines

Towards the 13-valent pneumococcal conjugate universal vaccination

(2013) Domenico Martinelli et al.   Human Vaccines & Immunotherapeutics

Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1×, 2×, or 4×) in healthy subjects aged 70 years or older

(2011) H. Lode et al.   VACCINE

Optimization and Validation of a Multiplex, Electrochemiluminescence-Based Detection Assay for the Quantitation of Immunoglobulin G Serotype-Specific Antipneumococcal Antibodies in Human Serum

(2009) R. D. Marchese et al.   Clinical and Vaccine Immunology

Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

(2009) Tamara Pilishvili et al.   JOURNAL OF INFECTIOUS DISEASES

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

(2009) Katherine L O'Brien et al.   LANCET

Trends in Acute Otitis Media-Related Health Care Utilization by Privately Insured Young Children in the United States, 1997-2004

(2008) F. Zhou et al.   PEDIATRICS

Acute Otitis Media in Children

(2008) David Greenberg et al.   PEDIATRIC DRUGS